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Submicroscopic recurrent 16p11.2 rearrangements are associat-
ed with several neurodevelopmental disorders, including autism,
mental retardation, and schizophrenia. The common 16p11.2
region includes 24 known genes, of which 22 are expressed in the
developing human fetal nervous system. As yet, the mechanisms
leading to neurodevelopmental abnormalities and the broader
phenotypes associated with deletion or duplication of 16p11.2
have not been clarified. Here we report a child with spastic
quadriparesis, refractory infantile seizures, severe global devel-
opmental delay, hypotonia, and microcephaly, and a de novo
598 kb 16p11.2 microduplication. Family history is negative for
any of these features in parents and immediate family members.
Sequencing analyses showed no mutations in DOC2A, QPRT,
and SEZ6L2, genes within the duplicated 16p11.2 region that
have been implicated in neuronal function and/or seizure related
phenotypes. The child’s clinical course is consistent with a rare
seizure disorder called malignant migrating partial seizure dis-
order of infancy, raising the possibility that duplication or
disruption of genes in the 16p11.2 interval may contribute to
this severe disorder.  2010 Wiley-Liss, Inc.
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INTRODUCTION
Recurrent rearrangements at 1q21.1, 15q11.2, 15q13.3, 16p13.11,
17q21.31, and 22q11.2 have been associated with various neuro-
psychiatric disorders such as mental retardation and schizophrenia
[Mefford, 2009; Mefford and Eichler, 2009]. Recently, recurrent
microdeletions in 15q11.2 and 16p13.11 have also been impli-
cated in certain idiopathic generalized epilepsies [de Kovel et al.,
2010], raising the possibility that other recurrent microdeletions
and their reciprocal microduplications may also be involved in
epileptogenesis.
Submicroscopic chromosomal rearrangements involving
16p11.2 have been associated with a number of clinical conditions
over the last several years. Microdeletions and duplications of
16p11.2 were first reported to have a significant association with
autism (OMIM 209850), a childhood neurodevelopmental disor-
der that emerges in the first three years of life and is characterized by
impairments in verbal and non-verbal communication, social
reciprocity, restricted interests, and repetitive behavior [Kumar et
al., 2008; Marshall et al., 2008; Weiss et al., 2008]. Microdeletions
and/or duplications in 16p11.2 have also been identified in patients
with mental retardation [Bijlsma et al., 2009], schizophrenia
[McCarthy et al., 2009], obesity [Bochukova et al., 2010], and in
normal individuals [Bijlsma et al., 2009]. The highly recurrent
nature of 16p11.2 rearrangements is thought to be mediated by
flanking segmental duplications or low copy repeats (LCRs) that
predispose this locus to non-allelic homologous recombination
(NAHR) [Kumar et al., 2008]. The wide range of phenotypes
associated with 16p11.2 deletions and duplications make this
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region a formidable challenge for genotype–phenotype correlation
studies, and more detailed clinical assessment of patients with
16p11.2 rearrangements are needed.
A number of epileptic syndromes of infancy and childhood are
known, with the genetic bases of some already elucidated [Nabbout
and Dulac, 2008]. Malignant migrating partial seizures of infancy
(MMPSI) is a rare, age-specific, epileptic encephalopathy; seizures
are refractory to vigorous antiepileptic therapy and after seizure
onset there is a profound loss or arrest of both cognitive and motor
milestones in survivors [Gross-Tsur et al., 2004]. Mutational
analysis of the KCNQ2, KCNQ3, SCN1A, SCN2A, CLCN2, and
MECP2 genes in infants clinically described as having malignant
migrating partial seizures have been carried out, but no pathogenic
alterations were detected [Coppola et al., 2006]. The genetic basis of
MMPSI remains as yet unknown.
Here, we report a patient with a de novo 16p11.2 microdupli-
cation and a history of severe static encephalopathy characterized
by spastic quadriparesis, severe global developmental delay, hypo-
tonia, and microcephaly. He also had severe refractory infantile
seizures, consistent with a diagnosis of MMPSI [Gross-Tsur et al.,
2004].
CLINICAL REPORT
A boy presented at 4 months of age to the Genetics Clinic for
evaluation of a seizure disorder. He was conceived by intrauterine
sperm injection. His mother, 34 years old at time of conception, had
a prior history of spontaneous abortion with the same partner; she
was treated with Repronex (a fertility medication containing follicle
stimulating hormone and luteinizing hormone which stimulates
the ovaries to produce eggs) and Ovidrel (a recombinant human
chorionic gonadotropin which promotes egg release) and was on
dexamethasone (a pregnancy category C medication) throughout
her pregnancy due to a history of congenital adrenal hyperplasia.
The patient was born at 38 weeks gestational age via augmented
vaginal delivery with a birth weight at the 40th centile (3.4 kg).
Apgar scores were 6 and 8 at 1 and 5 min, respectively. He exhibited
seizure activity starting at 1 day of life, characterized by generalized
stiffening, rolling back of the head, and high pitched crying which
lasted 30 sec to 1 min. His initial electroencephalogram (EEG)
showed frequent multifocal independent epileptiform discharges,
most frequently involving the temporal regions. Treatment with
phenobarbital, topiramate, and oxcarbazepine in the first 4 months
of life had no impact on seizure frequency. He continued to have
about four clinically recognized seizures daily, and made no devel-
opmental progress. Magnetic resonance imaging (MRI) of the brain
with spectroscopy at 2 months of age was unremarkable.
At 4 months of age, his weight, length, and head circumference
were at the 60th (7.1 kg), 37th (62.9 cm), and 9th (40.5 cm) centiles,
respectively. He had bilateral shifting esotropia, but no major
craniofacial dysmorphisms. Muscle bulk appeared normal but tone
was reduced in the truncal region and significant head lag was
noted. His suck and grasp reflexes were intact bilaterally. No
cutaneous pigmentary changes were noted by Wood’s lamp exami-
nation. Long-term video-EEG monitoring demonstrated frequent
multifocal epileptiform discharges within right and left temporal
regions, absence of normal sleep architecture, and numerous tonic
seizures (many subclinical), which lateralized predominantly to the
right temporal region, but were also present in the left temporal
region.
Introduction of treatment with vigabatrin at about 5 months of
age resulted in a substantial reduction in seizure frequency. Within
about 2 months, clinically detected seizures ceased, and did not
recur during treatment with vigabatrin. However, his neurodevel-
opment did not improve.
Repeat EEG at 9 months of age remained significantly abnormal,
with predominant rhythms at 4–4.5 Hz over the central and
occipital areas as well as intermittent faster (12–16 Hz) rhythms
over both the frontal and central areas and persistent sharp spike
waves at T4. EEG never demonstrated hypsarrhythmia. At
10 months of age, his weight, length, and head circumference were
at the 32nd (9.2 kg), 37th (72.3 cm), and 1st (42.8 cm) centiles,
respectively. He exhibited positional plagiocephaly, esotropia,
minimal head control, poor trunk control, and hypertonia of the
upper and lower extremities bilaterally. He intermittently focused
on the examiner.
At 27 months of age, his weight, length, and head circumference
were at the 46th (13 kg), 43th (89.3 cm), and 1st (45.7 cm) centiles,
respectively. An undescended right testicle was noted. He had
spastic quadriplegia, with minimal head control and poor trunk
control with intermittent extremity hypertonia on flexion and
extension. Clonus was noted of the left lower extremity. He did
not exhibit clear interest or awareness of his surroundings and
appeared to have no purposeful movements. A repeat MRI showed
mild hypoplasia of the corpus callosum but no degenerative
changes. At 34 months of age, his weight, length, and head circum-
ference were at the 61th (14.5 kg), 14th (90.3 cm), and 2nd
(46.1 cm) centiles, respectively. He continued to have esotropia
and exhibited myopathic facies.
Family history was negative for seizure, developmental delay,
psychiatric disorders, or mental retardation. In addition to the
mother, a maternal aunt was suspected to have adrenal hyperplasia.
There were two early infant deaths in distant cousins on the
maternal side of the family and a maternal second cousin with
epilepsy. There was no consanguinity in the family.
Molecular genetic testing included normal blood karyotype,
normal MECP2 sequencing and deletion and duplication analyses,
normal methylation PCR for SNRPN, normal CDKL5 sequencing
analysis, normal serum long chain fatty acids, acylcarnitines, trans-
ferrin, peroxisomal and plasma amino acid profiles, normal urine
organic acid profile, and negative urine S-sulfocysteine. Lactic acid
was at the upper normal level of 2.2 MEq/L and creatine phospho-
kinase was normal at 145 IU/L (normal range 38–240 IU/L). Serum
sialotransferrin testing for congenital disorders of glycosylation was
normal. An EMArray Cyto6000 oligonucleotide-based chromo-
somal microarray analysis at the Michigan Medical Genetics Lab-
oratories (MMGL) revealed a de novo 598 kb duplication of
16p11.2.
MATERIALS AND METHODS
DNA samples from the proband and his parents were obtained after
acquiring informed consent approved by the Institutional Review
Board for Human Subject Research at the University of Michigan.
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Array Comparative Genomic Hybridization (CGH)
Array CGH was conducted in MMGL at the University of Michigan
using the custom-designed EMArray Cyto6000 chip, implemented
on the Agilent 44K platform [Baldwin et al., 2008] which contains
43,103 oligonucleotide probes spaced on average every 75 kb with
whole genome coverage. DNA was isolated from blood samples
using a standard, semi-automated method (Biorobot M48 work-
station, Qiagen, Inc., Valencia, CA). The procedures for DNA
digestion, labeling and comparative genomic hybridization were
as described in Agilent Oligonucleotide-Based Array CGH for
Genomic DNA Analysis, Protocol version 4.0 June 2006 (Agilent
Technologies, Inc., Santa Clara, CA) with some modifications
[Baldwin et al., 2008]. The fluorescent signals on the array slides
were scanned into image files using GenePix 4200A scanner and
GenePix-Pro 6.1 software (Axon Instruments/Molecular Devices
Corp., Union City, CA). The array images were then imported and
evaluated by Agilent Feature Extraction 9.5 software. Data were
analyzed by Agilent’s CGH Analytics 3.5 software to determine
copy number differences and/or aberrations between the patient
DNA and the sex mismatched DNA [Baldwin et al., 2008].
Patient DNA was labeled with Cy3 and sex-mismatched pooled
reference DNA was labeled with Cy5. All the labeled DNA
samples were cleaned of reagents and unincorporated dyes by
vacuum filtration. Purified fluorescently labeled patient DNA
and reference DNA were mixed together, and hybridized to the
EmArray Cyto6000 [Baldwin et al., 2008]. Data were analyzed
by interpreting the resulting Cy3/Cy5 ratio. Numbering of
the Cyto6000 44K EMArray was according to Genome Build
UCSC hg 17 assembly (Build 35, May 2004). Chr16:29,500,284-
30,098,069 coordinates in hg17 remain unchanged in hg18 (March
2006) and hg19 (GRCh37) with 100% of bases and 100% of span, as
determined using the Convert function on the UCSC Genome
Browser (http://genome.ucsc.edu/).
Microsatellite Analysis and Quantitative-PCR
(qPCR)
Confirmation studies using microsatellite analysis and qPCR were
performed as previously described [Kumar et al., 2008].
DNA Sequencing
We sequenced three candidate genes (QPRT, DOC2A, and SEZ6L2)
in the patient and his parents. Primer sequences for DOC2A and
SEZ6L2 have been previously reported [Kumar et al., 2009]. Primer
sequences for QPRT were as follows: Exon 1F (50-GCTTCTGA
GTTCCCCATCAG-30) and Exon 1R (50-CCAGAGGAGGCAACA
AGG-30); Exon 2F (50-GGCCAGTTCCCAGTTTCACT-30) and
Exon 2R (50-CTGTTCACCCGGTCATGG-30); Exon 3F (50-GTGC
TGGGCCCTATCGTC-30) and Exon 3R (50-ACAAGCCAAGGG
GAGGTAAG-30); Exon 4.1F (50-GGACAACTTCAAGCCAGAGG-
50) and Exon 4.1R (50-ACATTTGCTGACCCCTCACT-30); and
Exon 4.2F (50-GGCACATTTGGCACTAGCTT-30) and Exon
4.2R (50-AAGGTTTTGGCCTGTCTGG-30). The following seque-
nces were added to each primer to facilitate sequencing: forward (F)
sequencing tail (50-TGTAAAACGACGGCCAGT-30) and reverse
(R) sequencing tails (50-CAGGAAACAGCTATGAC-30). DNA was
amplified in a reaction comprised of: 20 ng genomic DNA, 1
buffer I (1.5 mM MgCl2, Applied Biosystems, Foster City, CA),
1 mM dNTPs (Applied Biosystems), 0.4mM primer (each of for-
ward and reverse; IDT, Coralville, IA), and 0.25 U AmpliTaq Gold
(Applied Biosystems) in a total volume of 10ml. Thermocycling
conditions used ‘‘Touchdown’’ PCR [Korbie and Mattick, 2008].
PCR products were purified in a 10ml reaction comprised of 6.6 U
Exonuclease I and 0.66 U shrimp alkaline phosphatase that were
incubated at 37C for 30 min followed by 80C for 15 min. Se-
quencing reactions and data analysis were carried out as previously
described [Kumar et al., 2009].
Expression in Fetal Nervous System
Search for genes expressed in the human fetal nervous system was
carried out using the BGEE Gene Expression Evolution database
(http://bgee.unil.ch/bgee/bgee) release 06 (September 17, 2009)
based on Ensembl Genome Browser database release 55 (http://
www.ensembl.org/).
RESULTS
Array CGH analysis showed a 598 kb gain of genomic material at
16p11.2 (chr16:29,500,284–30,098,069; hg17), which contains 24
known genes (Fig. 1A,C and Table I). Array CGH analysis of both
parents of the proband indicated no 16p11.2 gain (data not shown).
The duplicated 16p11.2 region was flanked by segmental duplica-
tions (low copy repeats, LCRs) and adjacent areas of copy number
polymorphisms as noted in Figure 1B. Genes coding for both
known and hypothetical proteins within the duplicated region are
shown in Figure 1C and those coding for known proteins are
detailed in Table I. Microsatellite analysis was uninformative for
the duplication (data not shown) but qPCR analysis in the proband
and his parents confirmed the 16p11.2 microduplication results,
and further demonstrated that this rearrangement occurred de
novo (Fig. 2).
We sequenced the complete coding regions, associated splice
sites, and 50 and 30 untranslated regions (UTRs) of QPRT, DOC2A,
and SEZ6L2 in the proband and his parents (data not shown). Our
sequence data did not identify any putative pathogenic alterations.
DISCUSSION
We report here on a boy with a common recurrent 16p11.2
duplication and infantile refractory seizures whose clinical course
is consistent with MMPSI [Gross-Tsur et al., 2004]. The 598 kb
gain of genomic material in our patient is similar in size to
previously reported recurrent 16p11.2 duplications (600 kb) and
has approximately the same chromosomal boundaries [McCarthy
et al., 2009; Shinawi et al., 2009].
To date, there is minimal information about seizure phenotypes
in individuals with 16p11.2 deletions or duplications. Shinawi et al.
[2009] reported a series of 16p11.2 deletion and duplication
patients and found 3/10 duplication patients have seizures, one
confirmed as a de novo rearrangement. Bijlsma et al. [2009]
reported three patients with 16p11.2 deletions and history of
BEDOYAN ET AL. 1569
FIG. 1. Whole genome 44 K oligonucleotide-based microarray analysis. A: The 598 kb duplication at 16p11.2; (B) the segmental duplications and
copy number polymorphisms adjacent to the duplicated (597,786 bp) region (between the vertical red lines) as determined using the UCSC Genome
Browser (http://genome.ucsc.edu/); and (C) the genes within the 598 kb region (within the red rectangle) as determined using the Ensembl
Genome Browser (http://www.ensembl.org/).
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ALDOA 226 Fructose-bisphosphate aldolase A Y A glycolytic enzyme catalyzing the
reversible conversion of fructose-1,6-
bisphosphate to glyceraldehyde 3-
phosphate and dihydroxyacetone
phosphate
ASPHD1 253982 Aspartate beta-hydroxylase
domain containing 1
Y Catalyses oxidative reactions in
a range of metabolic processes
C16ORF53 79447 PTIP-associated 1 protein; PAXIP1-
associated protein; PA1
Y A component of a Set1-like
multiprotein histone
methyltransferase complex
CDIPT 10423 CDP-diacylglycerol-inositol 3-
phosphatidyltransferase
Y Phosphatidylinositol synthase
DOC2A 8448 Double C2-like domains, alpha Y Expressed mainly in the brain and
suggested to be involved in Ca(2þ)-
dependent neurotransmitter release
FAM57B 83723 Protein FAM57B; LOC83723 Y Member of the longevity-assurance





Y Involved in energy production
and conversion
HIRIP3 8479 HIRA-interacting protein 3 Y In vitro, the HIRIP3 gene product binds
HIRA, as well as H2B and H3 core
histones, indicating that a complex
containing HIRA-HIRIP3 could function




283899 INO80 complex subunit E Y Coiled-coil domain containing 95
KCTD13 253980 Potassium channel tetramerization
domain-containing protein 13
Y BTB/POZ domain-containing protein;
polymerase delta-interacting
protein 1; TNFAIP1-like protein
KIF22 3835 Kinesin-like DNA-binding protein Y Microtubule-dependent molecular
motors that transport organelles
within cells and move chromosomes
during cell division
MAPK3 5595 Mitogen-activated protein kinase 3;
ERK1; insulin-stimulated MAP2 kinase
Y Involved in cell cycle progression
MAZ 4150 Myc-associated zinc finger protein Y Purine-binding transcription factor;
serum amyloid A activating factor
MVP 9961 Major vault protein N Lung resistance-related protein
PPP4C 5531 Protein phosphatase 4 (formerly X),
catalytic subunit; PP4, PPH3
Y PP4 interacts with the survival of
motor neurons complex and enhances
the temporal localization of snRNPs
PRRT2 112476 Proline-rich transmembrane
protein 2; CD225
Y Interferon-induced transmembrane




Y Quinolinate acts as a potent
endogenous excitotoxin through
hyperstimulation of N-methyl D-
aspartate receptor in neurons
SEZ6L2 26470 Seizure related 6 homolog
(mouse)-like 2
Y Seizure related type I transmembrane
receptor protein
(Continued )
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developmental delay and seizures, one confirmed as a de novo
rearrangement. Kumar et al. [2008] also reported one autism
patient with a 16p11.2 deletion and history of seizures. Ghebranious
et al. [2007] described a 16p11.2 microdeletion in monozygotic
twins with complex phenotypes that include seizure disorder with
onset at 11.5 and 13 years of age, along with mental retardation and
heart defects. Although a strong association has been shown
between 16p11.2 deletion/duplication and autism [Kumar et al.,
2008; Marshall et al., 2008; Weiss et al., 2008] as well as autism and
epilepsy (present in 20% of autism cases) [Levisohn, 2007], more
detailed clinical history and correlation with incidence of epilepsy
(and/or autism) among patients with 16p11.2 chromosomal re-
arrangements is warranted.
Interestingly, microcephaly (circumference 5th centile) was
found in 6/10 patients with 16p11.2 duplication by Shinawi et al.
[2009] and in 1/9 patients with 16p11.2 duplication by McCarthy
et al. [2009] and Weiss et al. [2008]. These observations are
consistent with our patient’s microcephalic phenotype and high-
light the phenotypic variability associated with increased 16p11.2
dosage.
The 16p11.2 duplicated region contains 24 known protein-
coding genes, including QPRT, DOC2A, and SEZ6L2 (Table I)
which are implicated in neuronal function and/or seizure-related
phenotypes [Orita et al., 1995; Shimizu-Nishikawa et al., 1995;
Groffen et al., 2006; Guillemin et al., 2007; Kumar et al., 2009;
Vamos et al., 2009]. To our knowledge, no mutations in any of these
genes have been identified in humans with seizure disorders.
QPRT (OMIM 606248) encodes the quinolinate phosphoribo-
syltransferase enzyme that uses quinolinate as its substrate. Qui-
nolinate is an intermediate in the de novo synthesis pathway of
nicotinamide adenine dinucleotide (NAD) from tryptophan (the
kynurenine pathway) and acts as a potent endogenous excitotoxin
through hyperstimulation of the N-methyl D-aspartate receptor in
neurons [Guillemin et al., 2007]. Elevation of quinolinate levels
in the human brain has been postulated to be involved in the
pathogenesis of neurodegenerative and seizure disorders [Nemeth
et al., 2005; Vamos et al., 2009]. It is possible that the 16p11.2
duplication in our patient negatively affects the expression of
QPRT. An inverse correlation between copy number and gene
expression has been reported in a minority (10%) of copy number
variants (CNVs) [Stranger et al., 2007]. If such an inverse correla-
tion exists for the duplication and the abundance of QPRT product,
an overall decreased amount of functional quinolinate phosphor-
ibosyltransferase in our patient may lead to an increased level of
quinolinate, and consequently, an increased propensity for seizure.
Additional expression studies in our patient (or mouse models)
would be needed in order to test this hypothesis.
The DOC2A (MIM 604567) gene product is mainly expressed
in the brain, is suggested to be involved in Caþ2-dependent








SPN 6693 Sialophorin; CD43; GPL115 Y Important for immune function
and T-cell activation
TAOK2 9344 Serine/threonine-protein kinase TAO2 Y Prostate-derived STE20-like kinase 1
TBX6 6911 T-box 6 Y Anatomical structure morphogenesis
and mesoderm development
TMEM219 124446 Transmembrane protein 219 Y Conserved in chimpanzee, dog, cow,
mouse, and rat; function unknown
YPEL3 83719 Yippee-like 3 Y Conserved in chimpanzee, mouse,




653808 Zymogen granule protein 16 homolog N Jacalin-like lectin domain
containing; JCLN
aBased on BGEE gene expression evolution database (http://bgee.unil.ch/bgee/bgee) release 06 (September 2009) which is based on Ensembl release 55; N, no; and Y, yes.
FIG. 2. 16p11.2 Microduplication confirmation by qPCR. Probes for
SEZ6L2 and C16orf54 were as reported in Kumar et al. [2008].
Controls A and B are known to have two copies and one copy,
respectively, of SEZ6L2 and C16orf54.
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development, synaptic transmission, exocytosis, and transport
[Duncan et al., 2000; Groffen et al., 2006]. Although the role of
DOC2A in epilepsy and human development is unclear, mice with
Doc2a deletions show alterations in synaptic transmission and
learning and behavioral deficits [Sakaguchi et al., 1999].
SEZ6L2 is considered a seizure-related gene because a closely
related ortholog, Sez-6, is upregulated in response to seizure-
inducing reagents in mouse neurons [Shimizu-Nishikawa et al.,
1995]. SEZ6L2 is expressed in the human fetal brain, where expres-
sion is highest in post-mitotic cortical layers, hippocampus, amyg-
dala, and thalamus [Kumar et al., 2009]. Although mice with Sez6l2
deletions do not show any obvious defects in development or
behavior [Miyazaki et al., 2006], an association between a novel
SEZ6L2 coding variant R386H and autism has been proposed
[Kumar et al., 2009]. The extent to which DOC2A and SEZ6L2 are
involved in infantile epilepsy remains to be determined.
Although our patient’s clinical phenotype may be attribut-
able to the microduplication found in the 16p11.2 region (i.e., a
gene-dosage effect), the duplicated 16p11.2 region might also
contain mutations (such as a gain-of-function) in QPRT, DOC2A,
or SEZ6L2 that could contribute to his seizure phenotype. However,
we detected no sequence changes in the coding regions, splice
sites, or untranslated regions of QPRT, DOC2A, and SEZ6L2 in our
patient.
Our patient’s phenotype might also be caused by an insertion of
the duplicated region elsewhere in the genome, which could affect a
seizure-related gene at that location. However, this seems less likely
since common recurrent genomic rearrangements (such as recurrent
16p11.2 deletions and reciprocal duplications) often occur between
LCRs and are commonly caused by NAHR events [Stankiewicz and
Lupski, 2002; Mefford, 2009; Mefford and Eichler, 2009]. It remains
possible that other protein(s) in the duplicated 16p11.2 region (Fig.
1C or Table I) contribute to neuronal development and seizure
disorders. Testing the expression levels of QPRT, DOC2A, SEZ6L2,
and other genes in the duplicated region in patients with seizure
disorder and 16p11.2 rearrangement may help determine the im-
portance of these gene products in seizure risk. However, whether
white blood cells are a suitable proxy for brain (or other nervous
system) cells for such expression analyses is uncertain. Analysis of
mutant mouse models will be helpful for further delineating the
contributions of these genes to seizure phenotypes.
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